Follow
Paul Toren
Paul Toren
Verified email at crchudequebec.ulaval.ca
Title
Cited by
Cited by
Year
Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of …
L Klotz, C O'Callaghan, K Ding, P Toren, D Dearnaley, CS Higano, ...
Journal of Clinical Oncology 33 (10), 1151, 2015
1962015
Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities
P Toren, A Zoubeidi
International journal of oncology 45 (5), 1793-1801, 2014
1732014
Combination AZD5363 with enzalutamide significantly delays enzalutamide-resistant prostate cancer in preclinical models
P Toren, S Kim, T Cordonnier, C Crafter, BR Davies, L Fazli, ME Gleave, ...
European urology 67 (6), 986-990, 2015
1142015
Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer
PJ Toren, S Kim, S Pham, A Mangalji, H Adomat, EST Guns, A Zoubeidi, ...
Molecular cancer therapeutics 14 (1), 59-69, 2015
1002015
Small incidentally discovered testicular masses in infertile men—is active surveillance the new standard of care?
PJ Toren, M Roberts, I Lecker, ED Grober, K Jarvi, KC Lo
The Journal of urology 183 (4), 1373-1377, 2010
722010
Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients
FH Joncas, F Lucien, M Rouleau, F Morin, HS Leong, F Pouliot, Y Fradet, ...
The Prostate 79 (15), 1767-1776, 2019
602019
Results of a national population-based study of outcomes of surgery for renal tumors associated with inferior vena cava thrombus
P Toren, R Abouassaly, N Timilshina, G Kulkarni, S Alibhai, A Finelli
Urology 82 (3), 572-578, 2013
602013
Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study
P Toren, D Margel, G Kulkarni, A Finelli, A Zlotta, N Fleshner
bmj 346, 2013
592013
Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care?
L Klotz, P Toren
Current oncology 19 (s1), 13-21, 2012
572012
Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer
PJ Toren, ME Gleave
Asian journal of andrology 15 (3), 342, 2013
512013
Exercise effects on adipokines and the IGF axis in men with prostate cancer treated with androgen deprivation: A randomized study
D Santa Mina, MK Connor, SMH Alibhai, P Toren, C Guglietti, AG Matthew, ...
Canadian Urological Association Journal 7 (11-12), E692, 2013
502013
Periprostatic adipose tissue and prostate cancer progression: new insights into the tumor microenvironment
P Toren, V Venkateswaran
Clinical genitourinary cancer 12 (1), 21-26, 2014
452014
Combined AKT and MEK pathway blockade in pre-clinical models of enzalutamide-resistant prostate cancer
P Toren, S Kim, F Johnson, A Zoubeidi
PLoS One 11 (4), e0152861, 2016
382016
Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer
A Zardan, KM Nip, D Thaper, P Toren, S Vahid, E Beraldi, L Fazli, ...
Oncogenesis 3 (8), e115-e115, 2014
362014
Comparison of epidural and intravenous patient controlled analgesia in patients undergoing radical cystectomy.
P Toren, S Ladak, C Ma, S McCluskey, N Fleshner
The Canadian journal of urology 16 (4), 4716-4720, 2009
322009
Sex steroids in the tumor microenvironment and prostate cancer progression
C Boibessot, P Toren
Endocrine-Related Cancer 25 (3), R179-R196, 2018
312018
PEG10 is associated with treatment-induced neuroendocrine prostate cancer
S Kim, D Thaper, S Bidnur, P Toren, S Akamatsu, JL Bishop, C Colins, ...
Journal of Molecular Endocrinology 63 (1), 39-49, 2019
282019
Catastrophic sepsis and hemorrhage following transrectal ultrasound guided prostate biopsies
P Toren, R Razik, J Trachtenberg
Canadian Urological Association Journal 4 (1), E12, 2010
242010
Contemporary outcomes of palliative transurethral resection of the prostate in patients with locally advanced prostate cancer
J Pelletier, SJ Cyr, AS Julien, Y Fradet, L Lacombe, P Toren
Urologic Oncology: Seminars and Original Investigations 36 (8), 363. e7-363. e11, 2018
232018
Neutrophil-to-lymphocyte ratio as a predictive marker of response to abiraterone acetate: a retrospective analysis of the COU302 study
T Loubersac, M Nguile-Makao, F Pouliot, V Fradet, P Toren
European Urology Oncology 3 (3), 298-305, 2020
222020
The system can't perform the operation now. Try again later.
Articles 1–20